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Macrophage activation, enhancement of the ability of macrophages to kill
microbial pathogens (1, 2), is associated with complex modifications in the cells'
secretory, endocytic, locomotory, cytotoxic, and antigenic properties (3). Phe-
notypic changes correlated with activation include increased release ofhydrogen
peroxide, decreased secretion of protein, increased binding of particles coated
with IgG, decreased ingestion ofthese and other particles, and increased expres-
sion of la antigens. At least three biochemically defined cytokines have been
characterized as macrophage activators: interferon--y (IFN-y) (4), tumor necrosis
factor (TNF-a)' (5, 6), and lymphotoxin (TNF-0) (6). We know little about the
structures and modes of action of receptors for these cytokines. Experiments
with crosslinking agents suggest that molecules of -95 kD may be associated
with both IFN-y receptors (7) and TNF-a/# receptors (8).
Macrophages express a family of structurally and functionally related surface
glycoproteins: lymphocyte function-associated antigen-1 (LFA-1), Mac-1, and
p150/95 (9). Each ofthese molecules consists ofan antigenically distinct a chain
(M,. = 150-190 kD) noncovalently associated with an identical ,8 chain (M, = 95
kD) as an a,#, dimer (9, 10). Congenital inability to express the ,B chain results
in marked impairment of surface expression of all three heterodimers (11),
severe defects in leukocyte accumulation in vivo and adherence in vitro, and an
increase in life-threatening infections (12). In vitro studies indicate that at least
two ofthese proteins act as receptors for cell-bound ligands. Mac-1 mediates the
attachment and phagocytosis of particles coated with C3bi by granulocytes and
macrophages, and thus is identical to complement receptor type three (CR3) (13,
14). LFA-1 mediates the attachment of macrophages to tumor cells (15) and the
attachment of cytotoxic T cells to targets (9, 16). In addition, recent findings
implicate Mac-1 in binding by phagocytes of diverse microbes (17-21) and
bacterial cell wall lipopolysaccharide (LPS) (21).
In the foregoing studies, monoclonal antibodies to Mac-1 have helped clarify
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TABLE I
Monoclonal Antibodies
* Also recognizes # chain of Mac-1 and p150/95.
$ FcR for IgGI and IgG2b monomers and for immune complexes.
its functions by affording immediate inhibition of rapid cell responses, such as
binding and ingestion . In contrast, in the experiments described below, we
focused on delayed effects. We found that four features of activation of mouse
peritoneal macrophages induced by recombinant IFN-y (rIFN-y) were elicited
within 1-2 d of exposure to submicrogram concentrations of mAb to Mac-1 .
Moreover, F(ab')2 ofanti-Mac-1 mAb, or plating ofmacrophages on C3bi-coated
surfaces, inhibited the activation of macrophages by rIFN-y. These findings
assign a new function of Mac-1 (CR3): the ability, when suitably ligated, to evoke
various features of macrophage activation. These observations also raise the
possibility that Mac-1 participates in the activation of macrophages by cytokines.
Materials and Methods
Mice.
￿
Female mice 8-12 wks old were purchased from the Trudeau Institute, Saranac
Lake, NY (ICR and CD2F, strains) and Charles River Laboratories, Wilmington, MA
(CD, strain).
Macrophage Culture.
￿
Resident macrophages were washed from the peritoneal cavity
with RPMI 1640 (KC Biologicals, Inc., Lenexa, KS). After centrifugation at 170 g for 10
min, the cell pellets were resuspended in complete medium: RPMI 1640 containing 10%
heat-inactivated FCS (HyClone Laboratories, Logan, UT) and 2 mg/ 100 ml of gentamycin
sulfate (Schering Corp., Kenilworth, NJ). The level of contaminating LPS in complete
medium was <10 pg/ml as determined by a chromogenic Limulus amebocyte lystate test
(M. A. Bioproducts, Walkersville, MD) with LPS from Escherichia coli 0111 :114 (List
Biological Laboratories, Campbell, CA) as a standard. When erythrocytes were visible,
the cell pellet was treated with 0.2% NaCl for 30 s. Adherent macrophage monolayers
were obtained by plating the cells in 96-well plastic trays (Corning Glass Works, Corning,
NY) at 1 .5-2 x 105 cells/well, or on 13-mm glass coverslips with 106 cells/coverslip for 2
h at 37 °C in 5% C02, 95% air. Nonadherent cells were removed and freshly prepared
complete medium was added with the indicated experimental reagents.
Immunologic Reagents.
￿
The mAbs used are listed in Table I. IgG was purified from
hybridoma supernatants using anti-rat IgG coupled to agarose beads (HyClone) according
to the supplier's instructions. F(ab')2 of M1/70 was a generous gift from Dr. E. J. Brown,
Washington University, St. Louis, MO. Mouse rIFN-y synthesized in F .. coli (28), and
rabbit antiserum (titer, 6 .4 x 105 neutralizing units/ml) against recombinant mouse TNF-
a were the gifts of Genentech, Inc., South San Francisco, CA. rIFN-y had a specific
activity of 5.2 x 107 U/mg protein as assayed by protection of mouse L cells against
encephalomyocarditis virus in comparison to the National Institutes of Health IFN-y
standard, a purity of >99.96% by PAGE, and LPS contamination of <0.025 ng/mg
Clone Reactivity Isotype Refer-
ence
M1/70 a Chain of Mac-1 (CR3) IgG2b 16
M18/2 #Chain of LFA-1* IgG2a I1
FD441.8 a Chain of LFA-1 IgG2b 22
F4/80 gp 160 IgG2b 23
1121 .2 Iab,d ND 24
2AG2 FcR II$ IgG2b 25
HO-13-4 Thy-1.2 Igm 26
R4-6A2 Murine rIFN-,y IgGI 27DING ET AL.
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protein. Rabbit antiserum to this preparation of pure mouse rIFN-y was raised by us as
described elsewhere (Shparber, M., A. Ding, and C. Nathan, manuscript in preparation)
and had a neutralizing titer of 1 :1,000, as judged by its ability to inhibit completely the
enhancement of mouse peritoneal macrophage H202 releasing capacity in response to
100 antiviral units/ml of rIFN-y, when the antiserum and rIFN-y were added to the
macrophages simultaneously.
H202 Release.
￿
H202 secretion was detected fluorometrically by horseradish peroxidase
(HRP)-catalyzed oxidation of fluorescent scopoletin to a nonfluorescent product as de-
scribed in detail for macrophages in 96-well plates (29). The protein of cells adherent at
the start of the assay was measured by the method of Lowry et al. (30) with bovine serum
albumin as a standard. Specific release was calculated after subtracting H202 and protein
values for cell-free samples and expressed as nmol H202/mg cell protein/120 min.
la Induction.
￿
B21 .2 (Table 1) was iodinated with carrier-free Na'25I (New England
Nuclear, Boston, MA) by the Iodogen method (31). Quantitative binding studies were
performed at 0 ° C using coverslips with CD2F, macrophages cultured for 48 h in the
presence or absence of 100 U/ml rIFN-y or 1 tag/ml of M 1/70. Triplicate coverslips were
exposed to 0.25 ml of iodinated B21 .2 at a saturating level (0.3 ug/ml) for 2 h, then
washed by dipping in six beakers of 150 ml ice-cold 0.9% NaCl. Cells were solubilized in
0 .3 ml of 0 .1 N NaOH for y scintigraphy (Autogamma 5220; Packard Instrument Co.,
Downers Grove, IL) and for protein assay.
Protein Secretion.
￿
Quadruplicate coverslips of macrophages were incubated for 48 h in
the presence or absence of rIFN-y or mAbs, washed three times in 0.9% NaCl, and
incubated 4 h in 0.25 ml/coverslip of methionine-free RPMI plus 50 ACi/ml of [s5S]-
methionine, sp act 1,000 Ci/mmol (New England Nuclear). The conditioned medium was
pooled and precipitated with 7% ice-cold TCA in the presence of 75 ;1g/ml ofMicrococcus
leisodeikticus (Sigma Chemical Co., St. Louis, MO) as a carrier. The pellet was washed
twice with 5% TCA and solubilized in 50 Al of 0.0625 M Tris buffer containing 1 % of
SDS. Radioactivity was determined in a scintillation counter. Monolayers of macrophages
were solubilized with 0 .3 ml of 0.1 N NaOH and the protein contents were assayed by
the method of Lowry et al . (30).
T Cell Depletion.
￿
Equal volumes of peritoneal cells (7 x 106 per 1 .5 ml), 1 :5 dilution
of anti-Thy-1 .2 mAb hybridoma supernatant, and complement (baby rabbit serum,
Cedarlane Laboratory, Hornby, Ontario, Canada) were incubated together at 37'C for
1 h in a water bath . All reagents were diluted in RPMI 1640 with 0.3% bovine serum
albumin and 25 mM Hepes buffer, pH 7 .2 (32). The cells were washed twice in RPMI
1640 before adherence.
Preparation ofZymosan, Heat-killed Bacteria and IgG-coated Glass Beads.
￿
Suspensions of
zymosan (ICN, Plainview, NJ) were prepared by the method of Bonney et al. (33). Listeria
monocytogenes (Trudeau Institute, Saranac, NY) were grown overnight to log-phase in
trypticase soy broth (BBL; Becton Dickinson Co., Cockeysville, MD). After immersion in
a boiling water bath for 10 min, they were washed twice with PBS, suspended at 5 x 109
cells/ml in PBS, and stored in aliquots at -70 ° C. IgG-coated glass beads were prepared
as described by Aderem et al. (34). When used as triggering agents in the H202 assay,
particles were substituted for phorbol myristate acetate (PMA) in the assay mixture.
Binding and Phagocytosis.
￿
Sheep erythrocytes were coated with rabbit IgG (EIgG) or
human C3bi (EC3bi) as described (35). Monolayers of phagocytes on 13-mm glass cover-
slips were washed and overlaid with 3 x 105 E. After a 45 min incubation at 37'C, the
coverslips were dipped in PBS to remove unbound E, and attachment was scored in a
phase-contrast microscope. Data are presented as attachment index, the number of E
bound per 100 phagocytes. Phagocytosis was scored in a similar fashion after uningested
E were lysed by brief exposure to distilled water.
Preparation ofMurine C3bi-coated Plates.
￿
Plastic surfaces were coated with C3bi by the
action of whole mouse serum on an IgM-coated surface as described (36). In brief, a
plastic plate was coated consecutively with poly-L-lysine, dinitrophenol (DNP) and mono-
clonal anti-DNP IgM (a gift of Dr. V. Nussenzweig). Then freshly prepared mouse serum736
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FIGURE 1.
￿
In vitro activation of resident mouse peritoneal macrophages with mAbs to CR3.
Macrophages were incubated with hybridoma supernates MI/70, 2AG2, F4/80, FD441.8
(each50%vol/vol), M18/2 IgG (1 jug/ml) or rIFN-y (100 U/ml)for48 h. Stimulation of H202
release by 100 ng/ml of PMA was assayed. The results are representative of seven separate
experiments. Bars are means ± SE for triplicates.
was added and incubated at 37°C for 30 min. Control wells were filled with PBS instead
of serum in the last step.
Results
Activation of Macrophage H202-releasing Capacity by mAb for Mac-1.
￿
Resident
peritoneal macrophages from normal mice release little H202 when triggered
with PMA, parasites, or other stimuli (37, 38). However, macrophages activated
in vivo by inflammatory or infectious agents (39), and both in vivo and in vitro
by rIFN-y (4, 40), display an enhanced capacity to release H202 upon subsequent
triggering. Fig. 1 compares PMA-triggered H202 release from resident perito-
neal macrophages incubated for 48 h with five mAbs directed against macro-
phage surface antigens (Table 1). M1/70, which recognizes the a subunit of Mac-
1, was as effective as rIFN-y in enhancing macrophage H202-releasing capacity.
In seven such experiments, M1/70 induced 13 ± 4-fold as much H202 releasing
capacity as seen in medium alone (mean ± SE). At the dilutions used, M1/70
contained <0.1 ng/ml LPS. LPS at this concentration was unable to mimic the
effect of M1/70 (data not shown). Also effective was M18/2, directed to the 0
chain of the LFA-1 and Mac-1 family. In four such experiments, M18/2 resulted
in 14 ± 4-fold enhancement of H202-releasing capacity compared to control.
However, other isotype-matched mAbs were ineffective, including thosedirected
to the a chain of LFA-1 (FD441 .8) and to FcR (2.4G2).
M18/2 was used in the above experiments as pure IgG, indicating that its
action was not attributable to other components of hybridoma-conditionedc
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FIGURE 2.
￿
Dose response of M1/70-mediated activation. Monolayers of macrophages were
cultured in varying concentrations of purified M1/70 IgG (0) or 10,ug/ml of 2AG2 IgG (0)
for48 hbefore H202 assay. The resultsare representative ofsix separate experiments. Values
are means ± SE for triplicates. Where no error bars are shown, they are smaller than the
symbol .
medium. Similarly, Fig. 2 shows that purified M1/70 IgG was as active as M1/70
hybridoma supernatant. At 1 Ag/ml, M1/70 IgG was as effective in potentiating
the release of H202 as the optimal concentration of rIFN-y. In six such experi-
ments, the concentration of Ml/70 IgG resulting in 50% of the maximal
activation of macrophage H202-releasing capacity averaged 0.18 ± 0.03 ug/ml.
Ml/70 IgG at 1 wg/ml was used in all further experiments.
The action of M1/70 was not mediated by its Fc domain. A monoclonal
antibody against FcR (2.4G2) did not affect release ofH202 (Fig. 2), nor did it
block the action of Ml/70 (data not shown). Moreover, F(ab')2 of M1/70
enhanced H202-releasing capacity (Fig. 3). Unexpectedly, Ml/70 F(ab')2 mark-
edly inhibited the activating effect ofrIFN-y when both were added simultane-
ously (Fig. 3).
Because a stable preparation of soluble C3bi is not available for testing, to
observe whether interaction ofCR3 with its natural ligand would enhance H202
releasing capacity, we plated macrophages on plastic surfaces coated with Mi.
48 h later, the plates were washed and tested for H202 in response to PMA. The
H202-releasing capacity of such cells was no greater than for controls, and in
fact, such cells responded less well to rIFN-y (Fig. 4).
Time Course of M1170-mediated Activation.
￿
rIFN-y requires 1-2 d to induce
substantial H202-releasing capacity and antiprotozoal activity in vitro (4). Acti-
vation mediated by M1/70 followed a similar time course (Fig. 5).738
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￿
Effect of F(ab')2 of M1/70 on H202 release. Cells were incubated in the absence
(open) or presence (shaded) of 1 jug/ml of F(ab')2 with or without rIFN-1' (100 U/ml) for 48 h
before assay. The results are representative of four separate experiments and are means± SE
for triplicates.
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FIGURE 4.
￿
Effect of C3bi-coated surface on H202 release. Cells were plated on IgM- (open)
or IgMC3bi- (shaded) wells. Other conditions were the same as Fig. 3. The results are
representative ofthree separate experiments and thedata are means± SE for triplicates.DING ET AL.
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FIGURE 5.
￿
Time course of MI/70 activation. Complete medium with 1 ug/ml of purified
M1/70 was added to macrophage monolayers at different time points. AllH202 release assays
were performedtogether 72 hafterplating thecells.Time of incubation indicates theduration
between addition of antibody and the assay. The results are representative of five separate
experiments and the values are means± SE for triplicates.
TABLE 11
Induction ofIa Antigen on Resident Macrophages
* Control coverslips were preincubated for 48 hin medium alone. Values
are means ± SE for triplicates. If expressed as molecules of anti-Ia (X
10-8) per microgram cell protein, the results would be 2.31 ± 0.20
(controls); 4.50 ± 0.49 (M1/70-treated); and 7.10 ± 1.6 (rIFN-y-
treated).
$ 1 Wg/ml for 48 h.
¢ 100 U/ml for 48 h.
q Mean ± SE of the mean values for the individual experiments.p value:
M1/70 vs. control, p < 0.05; rIFN-y vs. control, p < 0.1 ; rIFN-'Y vs.
M1/70, p > 0.1 (Student's t-test for paired means).
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Induction of Ia Antigen.
￿
Like IFN-y (24, 41), M1/70 induced la antigens on
resident peritoneal macrophages. In fact, the extent ofinduction by the cytokine
and by the mAb did not differ to a statistically significant degree (Table II).
Inhibition of Protein Secretion.
￿
Activation ofmacrophages by rIFN-y has been
shown to inhibit overall protein synthesis (42). We found that exposure to rIFN-
ti also decreased the overall secretion of protein (Table III). Treatment of
macrophages with MI/70 induced the same effect. In fact, the patterns of
individual proteins, as reflected in autoradiograms after SDS-PAGE, closely
resembled that reported with macrophages activated in vivo (not shown) (43 and
Shparber et al., manuscript in preparation).
Inhibition ofParticle-induced H202 Release and Phagocytosis.
￿
Even though rIFN-
Exp.
Percent of control
M1/70-treated*
(cpm/ug protein)*
rIFN-y-treated4
1 164 ± 12 284 ± 13
2 155±12 173±12
3 251 ±44 534 ± 18
4 213 ± 18 393 ± 30
5 209 ± 12 ND
6 175±22 140±9
Mean ± SEA 195 ± 14 305 ± 65740
￿
ACTIVATION OF MACROPHAGES BY MONOCLONALS TO MAGI
Mean ± 53±8.2 59±4.6
Control coverslips were incubated with medium alone .
I jAg/mI for 48 h .
100 U/mI for 48 h,
FIGURE 6.
￿
H202 release ofmacrophages triggered with different stimuli . Resident peritoneal
macrophages were cultured in the absence (11) or the presence of 100 U/ml rIFN-7 (P or I
jAg/ml MI/70 (W for 48 h . H202 release was assayed upon treatment with (A) 100 ng/ml
PMA, (B) 200 ug/ml zymosan, (C) 2 mg/ml IgG-coated glass beads, or (D) 10' heat-killed
listeria . The results are representative of three separate experiments . Values are means ± SE
for triplicates .
7 enhances FcR expression and binding of EIgG to macrophages, it decreases
the ingestion of these particles (44-46). Likewise, activation of macrophages in
vivo inhibits their phagocytosis of a variety of particles (47, 48) . Nonetheless,
activation of macrophages both in vitro and in vivo generally increases the
amount of H202 they release in response to contact with particles. In contrast,
MI/70-treated macrophages released no more H202 than controls when chal-
lenged with unopsonized zymosan, IgG-coated glass beads, or heat-killed listeria,
even though the response to PMA was increased an average of fivefold in the
same set of experiments (Fig . 6) . The inhibition seen with zymosan and bacteria
might be attributed to the involvement of CR3 in their binding (18, 19) .
However, this would not explain the inhibition seen with IgG-coated beads.
The effect ofM1/70 on the morphology of the cells may in part expl
Percent
Exp .
of control (cpm/,ug protein)*
M1/70-treated rIFN--y-treatedi
1 617
2 48
3 62DING ET AL.
￿
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above results. Thus, in contrast to the spreading induced by rIFN-7, M1/70
induced marked cell-cell aggregation (Fig. 7). The clusters arose through aggre-
gation rather than proliferation, because such clusters contained no more cells
and incorporated no more ['H]thymidine than controls (data not shown) . Aggre-
gation of macrophages might restrict their ability to make contact with particles.
However, M1/70 also suppressed the phagocytic capacity of macrophages
plated sparsely so that aggregates did not form. As shown in Table IV, under
these conditions, EIgG were bound better by M1/70-treated macrophages than
by control cells, but their uptake was almost completely suppressed. This was
similar to the effect of rIFN-y, but more marked.
Thus, Ml/70 interfered with the macrophage response to particles in at least
three ways: blockade ofa receptor (CR3) involved in binding of some particles,
induction ofcell clusteringindensely plated cultures, and inhibition ofsignalling
by FcR without inhibition of its capacity to bind.
Evidence against Mediation of M1 /70's Effects by Endogenous IFN-'y or TNF-a.
All actions of M1/70 described so far, except for its induction ofcell clustering,
resembled those of rIFN-.y. Thus, we considered the possibility that Ml/70
induced the release of IFN-7 in the adherent peritoneal cell cultures, and that
IFN-y mediated its effects. Since the most likely source of IFN-'y was contami-
nating T cells, we first tested the effect of depleting T cells with anti-Thy-1 .2
mAb and complement under conditions where 99% of thymocytes were lysed.
Table V shows the results from three such experiments. Depletion ofTcells did
not affect the ability of M1/70 to activate macrophages.
Nonetheless, because NK cells or macrophages could also be sources of IFN-
7 (49-52) or TNF-a (53, 54), we tested the effects ofantibodies that neutralize
IFN-'y or TNF-a. Neither mAb nor polyclonal antiserum raised to murine rIFN-
7 blocked MI/70-mediated enhancement of H202-releasing capacity, although
both antibodies abrogated the effect of exogenous rIFN-7 (Fig. 8). Similarly,
rabbit antiserum against murine rTNF-a at 100 neutralizing units/ml did not
have any effect on M1/70-mediated macrophage activation (data not shown) .
Discussion
Cell differentiation is controlled in large part by interactions of cells with
extracellular molecules. The latter may include specific components of the
extracellular matrix orneighboringcells. Ithasnotbeen clear, however, whether
the cell surface receptors known as adhesion molecules play a role in signalling
changes in phenotype. We show here that mAbs that ligate the adhesion-
promoting receptor, Mac-1 (CR3), on resident mouse peritoneal macrophages
elicited differentiative changes associated with macrophage activation.
These changes included enhanced capacity to secrete H202, decreased secre-
tion of proteins, increased expression of la antigen, and decreased phagocytosis
of a variety of particles, including IgG-coated erythrocytes. Decreased phagocy-
tosis by M1/70-treated macrophages was so marked that we could not assess the
ability of anti-Mac-l-treated macrophages to kill intracellular pathogens (not
shown) . In this respect, anti-Mac-I mAbs differed from rIFN-y. Otherwise, the
changes in macrophages induced by mAbs to Mac-1 closely resembled those
induced by rIFN-y, as well as by TNF-a and TNF-,# (6) in type, extent, and time742
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Aggregation of MI/70-treated macrophages. Cellswere incubated with (A) me-
(B) I Ag/ml of MI/70, or (C) 100 U/ml of rIFN-y for 48 h at 37°C .* 1 kg/ml for 48 h.
$ 100 U/ml for 48 h.
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TABLE IV
Effect ofM1170 on Attachment and Phagocytosis ofOpsonized
Erythrocytes
TABLE V
Effect ofDepletion of T Cells
Results are means for triplicates.
* 1 h at 37°C, concentrations indicated in Materials and Methods.
1 dag/ml for 48 h.
course. Equally surprising, F(ab')2 of M1/70, or modulation of Mac-1 by plating
macrophages on C3bi-coated surfaces, inhibited macrophage activation by
rIFN-y .
The mAb appeared to work by binding Mac-1 itself, rather than crossreacting
with other molecules or FcR. Thus mAbs were effective when directed to either
the a chain or the antigenically dissimilar ß chain ofMac-1, but not when reactive
with the a chain of LFA-1, nor with two other macrophage surface antigens of
similar abundance. Anti-FcR mAb neither mimicked nor blocked the effect of
MI/70, nor was the Fc portion of Ml/70 necessary.
Ligation of Mac-l did not appear to activate macrophages by inducing the
releaseof IFN-y or TNF-a in the cultures. T cells, which may have contaminated
the cultures, do not express Mac-1 and thus are unlikely to respond to anti-Mac-
1 mAbs. In any case, treatment withanti-Thy-1 .2 plus complement had no effect
(Table V). NK cells, which both express Mac-1 and secrete IFN-y (49, 50) and
TNF-a-like substances (54), are exceedingly rare in adherent peritoneal cell
populations from normal, untreated mice (55). In any case, M1/70-induced
activation was not inhibited by neutralizing monoclonal or polyclonal antibodies
to murine IFN-y or TNF-a. The lack ofinhibition ofM1/70-induced activation
by antibodies to TNF-a does not rule out a possible role for nonsecreted TNF-
H202 produced (nmol/mg protein/ 120
Exp. Incubation with:
min)
None
after
Antibody
pretreatment*
C,
with:
Antibody
+C 1
1 Medium 20 67 33 47
M1/70 158 136 118 168
2 Medium 4 12 12 12
M1/70 186 142 199 132
3 Medium 33 50 27 46
M1/70 168 229 207 242
Treatment of
macrophages
Attachment
EC36i
index
EIgG
Phagocytic
EC36i
index
EIgG
Control 547 596 24 312
M1/70* 172 746 4 4
rIFN-yt 268 1024 7 122744
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￿
Effects of anti-rIFN--y antibodies on activation by M1/70. Cells were incubated
with 100 U/ml of rIFN-y or 1 Ag/ml of M1/70 in the absence (open) or presence (shaded) of
(A) mAb R4-6A2 (50%, vol/vol), (B) antiserum (1 :2,500). PMA-dependent H202 release was
then determined. The results are representative of four separate experiments and are means
± SE for triplicates.
a in this phenomenon . Since microbes and microbial products now known to
bind Mac-1 are potent inducers of TNF-a release from macrophages, it would
be of interest to examine induction of TNF-a mRNA in response to anti-CR3
mAbs.
Our observations with F(ab')2 of M1/70 and with solid-phase C3bi suggest
that CR3-reactive ligands may either induce or inhibit macrophage activation.
The factors determining the outcome are unknown, but may include the degree
or time course of CR3 crosslinking or clustering. These considerations may
pertain to the conflicting observations on induction or inhibition of macrophage
activation by microbial products now known to bind to CR3. For example, LPS
can both enhance macrophage respiratory burst capacity (56) and inhibit the
enhancement of respiratory burst capacity by other activators (A. Ding and C.
Nathan, manuscript in preparation). Similarly, microbial cell wall preparations
both elicit (57) and inhibit (58) various features of activation. Further studies of
the interaction of these agents with CR3 may help explain these seemingly
paradoxical observations. At present, we have no proofthat macrophage activa-
tion can ensue from the binding of C3bi to CR3, although this seems likely.
The present findings suggest the existence of an intimate but undefined
relationship between Mac-1 and cytokines that activate macrophages. Four such
relationships are under consideration. (a) The ability of anti-Mac-1 mAbs to elicit
several features of macrophage activation in common with cytokines may reflect
the independent transduction of similar signals by mAb-ligated Mac-1 and by
cytokine-ligated receptors. (b) Receptors for cytokines might be structurally
similar to Mac-1. Mac-1 is clearly not identical with IFN-y receptors or TNF-a
receptors, given the different distribution and abundance of these molecules on
various cell types. However, it is possible that a 0 chain similar to that of Mac-1
is associated with IFN-y receptors and TNFa receptors, and that mAbs to the 0We thank M. Shepard of Genentech, Inc. for rIFN-y and anti-TNF-a antiserum; G. L.
Spitalny for hybridoma R4-6A2; E. J. Brown for F(ab')2 of M1/70; V. Nussenzweig for
anti-DNP IgM; and P. Rodricks and M. Jong for technical assistance.
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chains and certain epitopes on a chains (such as M1/70) could mimic the binding
of IFN-y or TNF-a. (c) Ligation of Mac-1 might cause cytokine receptors to
transduce signals in the absence of their ligands, by analogy with interactions
recently reported for colony-stimulating factors (59). (d) Ligated cytokine recep-
tors might transduce their macrophage-activating signals via an interaction with
Mac-1 . mAb to Mac-1 could mimic this interaction and bypass the cytokines.
These speculations do not make clear whether F(ab')2 of M1/70 or engagement
of CR3 by C3bi on the vessel surface suppressed rIFN-y-induced activation by
making Mac-1 inaccessible to rIFN-y, or by delivering a prevailing negative
signal.
It is now evident that a thorough understanding of the physiologic functions
of Mac-1 will require further characterization not only of Mac-1, but also of the
receptors for macrophage activating factors.
Summary
Several features of activation of mouse peritoneal macrophages were elicited
by 1-2-d exposure to submicrogram concentrations of anti-Mac-1 (M1/70), a rat
monoclonal antibody that reacts with the a chain of complement receptor type
3 (Mac-1). The changes induced included enhanced capacity to secrete H202
when triggered with PMA, decreased secretion of proteins, increased expression
of la antigen and decreased phagocytosis of particles. These changes closely
resembled those induced by rIFN-y in type, extent, and time course. The
concentration of MI/70 IgG resulting in 50% of the maximal activation of
macrophage H202-releasing capacity averaged 0.18 ± 0.03 Ag/ml. This activation
was not blocked by anti-FcR mAb, and could be reproduced with M18/2, a mAb
against (3 chain of Mac-1, suggesting that a direct ligation of Mac-1 with mAb
was responsible for the activation. Neither depletion of T cells nor addition of
neutralizing Abs to IFN-y or TNF-a prevented M1/70-mediated macrophage
activation . Moreover, F(ab')2 of M1/70, or plating of macrophages on C3bi-
coated surfaces, inhibited the activation of macrophages by rIFN-y . These
findings suggest that Mac-1 (CR3) may play an important role in macrophage
activation .
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